Maravai LifeSciences (MRVI) Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRVI shares.
View MRVI analyst ratings or view top-rated stocks.

9 Wall Street research analysts have issued twelve-month price targets for Maravai LifeSciences' stock. Their MRVI share price forecasts range from $14.00 to $29.00. On average, they predict the company's stock price to reach $19.80 in the next twelve months. This suggests a possible upside of 44.5% from the stock's current price.
View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts.

Maravai LifeSciences' stock was trading at $14.31 at the beginning of the year. Since then, MRVI stock has decreased by 4.3% and is now trading at $13.70.
View the best growth stocks for 2023 here.

Maravai LifeSciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 7,270,000 shares, an increase of 21.2% from the April 30th total of 6,000,000 shares. Based on an average trading volume of 2,290,000 shares, the short-interest ratio is presently 3.2 days. Approximately 6.7% of the company's shares are sold short.
View Maravai LifeSciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our MRVI earnings forecast.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) posted its earnings results on Monday, May, 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.01. The business earned $79.03 million during the quarter, compared to analyst estimates of $79.72 million. Maravai LifeSciences had a trailing twelve-month return on equity of 38.41% and a net margin of 21.36%. The company's quarterly revenue was down 67.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.54 earnings per share.

ETFs with the largest weight of Maravai LifeSciences (NASDAQ:MRVI) stock in their portfolio include Direxion mRNA ETF (MSGR), Janus Henderson Small Cap Growth Alpha ETF (JSML), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Putnam BioRevolution ETF (SYNB), Distillate Small/Mid Cash Flow ETF (DSMC), Renaissance IPO ETF (IPO), Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG) and Vanguard U.S. Quality Factor ETF (VFQY).

Maravai LifeSciences updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share guidance of $0.27-$0.33 for the period, compared to the consensus earnings per share estimate of $0.35. The company issued revenue guidance of $400.00 million-$440.00 million, compared to the consensus revenue estimate of $430.17 million.

(MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Maravai LifeSciences trades on the NASDAQ under the ticker symbol "MRVI."

Maravai LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Thrivent Financial for Lutherans (3.21%), BlackRock Inc. (2.31%), JPMorgan Chase & Co. (1.52%), Clearbridge Investments LLC (1.27%), Renaissance Technologies LLC (1.25%) and Mackenzie Financial Corp (0.99%).

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRVI stock can currently be purchased for approximately $13.70.

Maravai LifeSciences (NASDAQ:MRVI) has a market capitalization of $3.44 billion and generates $883 million in revenue each year. The company earns $220.21 million in net income (profit) each year or $1.15 on an earnings per share basis.

The company employs 470 workers across the globe.

Maravai LifeSciences' mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.maravai.com. The company can be reached via phone at 858-546-0004 or via email at ir@maravai.com.